CAJ | 학술논문

目的探讨分化型甲状腺癌(DTC)并远处转移患者接受131Ⅰ治疗的临床效果.方法 50例DTC术后患者,根据DTC转移部位给予一次和分次治疗,总去除剂量为(370～740)×107Bq,间隔时间为4个月.结果 50例DTC术后患者中,35例首次清除剩余甲状腺组织成功(70.0%);转移癌18例中,治愈6例(33.3%),有效8例(44.4%),无效4例(22.2%);甲状腺转移患者治疗前甲状腺球蛋白水平明显高于无甲状腺转移(t=2.715,P<0.01),治疗后明显下降(t=2.844,均P<0.01);治疗组治疗后CD4+、DD8+、CD4+/CD8+含量[(26.5±4.7)%、(39.4±5.7)%、(0.6±0.4)%]均低于治疗前[(38.3±5.6)%、(29.8±6.9)%、(1.4 ±0.5)%](t=2.345,t=2.244,t=2.451,均P<0.05).结论 DTC术后131Ⅰ治疗可以有效清除剩余甲状腺组织,治疗转移灶.
목적 탐토분화형갑상선암(DTC)병원처전이환자접수131Ⅰ치료적림상효과.방법 50례DTC술후환자,근거DTC전이부위급여일차화분차치료,총거제제량위(370～740)×107Bq,간격시간위4개월.결과 50례DTC술후환자중,35례수차청제잉여갑상선조직성공(70.0%);전이암18례중,치유6례(33.3%),유효8례(44.4%),무효4례(22.2%);갑상선전이환자치료전갑상선구단백수평명현고우무갑상선전이(t=2.715,P<0.01),치료후명현하강(t=2.844,균P<0.01);치료조치료후CD4+、DD8+、CD4+/CD8+함량[(26.5±4.7)%、(39.4±5.7)%、(0.6±0.4)%]균저우치료전[(38.3±5.6)%、(29.8±6.9)%、(1.4 ±0.5)%](t=2.345,t=2.244,t=2.451,균P<0.05).결론 DTC술후131Ⅰ치료가이유효청제잉여갑상선조직,치료전이조.
Objective To investigate the effect of iodine-131(131Ⅰ) therapy on patients with differentiated thyroid carcinoma concurrent metastases.Methods 50 cases with differentiated thyroid carcinoma after operation ac-cording to metastaticsites were given one of fractionated treatment,a total removal of dose(370～740)×107Bq,inter-val of 4 months.Results 35 of 50 patients(70.O%) had successful ablation of residual thyroid tissue after the first administration of radioiodine.Metastatic carcinoma in 18 cases,6 cases(33.3%) were cured,effective treatment was shown in 8 cases(44.4%)and treatment failure in 4 cases(22.2%);Thyroid metastasis before treatment were signifi-cantly higher than non-HTG thyroid metastasis(t=2.715,P<0.01),decreased significantly after treatment(t=2.844,all P<0.01);The contents of CD4+、CD8+、CD4+/CD8++ in treatment group after treatment[(26.5±4.7)%、(39.4±5.7)%、(0.6±0.4)%] were lower than before treatment[(38.3±5.6)%、(29.8±6.9)%、(1.4±0.5)%](t=2.345,t=2.244,t=2.451,all P<0.05).Conclusion Treatment with multiple hlsh doses of 131Ⅰ was safe and effective with little adverse side-effect.